Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies

被引:38
作者
Alkharabsheh, Omar [1 ]
Frankel, Arthur E. [1 ]
机构
[1] Univ S Alabama, Mitchell Canc Inst, Div Med Oncol, Mobile, AL 36604 USA
关键词
SL-401 (tagraxofusp); diphtheria immunotoxin; adverse events; Myeloid neoplasms; TOXIN-INTERLEUKIN-3 FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; TUMOR MICROENVIRONMENT; TARGETED THERAPY; RECEPTOR; IMMUNOTOXINS; PROGENITORS; DT(388)IL3; SURVIVAL;
D O I
10.3390/biomedicines7010006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater understanding of the molecular biology of leukemia stem cells are in rapid progress. Targeted therapies are currently being used in clinical practice with reasonable response rates, but a cure is being achieved in only a small percentage of patients, most likely due to tumor mutational heterogeneity. A genetically engineered diphtheria toxin fused with interleukin-3 (SL-401 or tagraxofusp) has shown robust activity in blastic plasmacytoid dendritic cell neoplasm and promising response rates in different myeloid malignancies, including eradication of minimal residual disease. Multiple clinical trials are being conducted using this drug and the preliminary results are encouraging. This article reviews the clinical trials for SL-401, its mechanism of action, clinical activity, and the adverse event profile.
引用
收藏
页数:9
相关论文
共 30 条
[1]  
Alsidawi S., 2016, BLOOD, V128, DOI DOI 10.1182/BL00D.V128.22.4789.4789
[2]  
[Anonymous], 2016, BLOOD
[3]  
[Anonymous], 2017, BLOOD S1
[4]  
[Anonymous], 2016, BLOOD
[5]   Treatment of cutaneous T cell lymphoma: Current status and future directions [J].
Apisarnthanarax N. ;
Talpur R. ;
Duvic M. .
American Journal of Clinical Dermatology, 2002, 3 (3) :193-215
[6]  
Aruna G, 2006, J STEM CELLS REGEN, V1, P31
[7]   Diphtheria toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice [J].
Black, JH ;
McCubrey, JA ;
Willingham, MC ;
Ramage, J ;
Hogge, DE ;
Frankel, AE .
LEUKEMIA, 2003, 17 (01) :155-159
[8]   Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics [J].
Candolfi, Marianela ;
King, Gwendalyn D. ;
Yagiz, Kader ;
Curtin, James F. ;
Mineharu, Yohei ;
Muhammad, A. K. M. Ghulam ;
Foulad, David ;
Kroeger, Kurt M. ;
Barnett, Nick ;
Josien, Regis ;
Lowenstein, Pedro R. ;
Castro, Maria G. .
NEOPLASIA, 2012, 14 (08) :757-+
[9]   Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention [J].
Chang, F ;
Steelman, LS ;
Lee, JT ;
Shelton, JG ;
Navolanic, PM ;
Blalock, WL ;
Franklin, RA ;
McCubrey, JA .
LEUKEMIA, 2003, 17 (07) :1263-1293
[10]  
Feuring-Buske M, 2002, CANCER RES, V62, P1730